Total revenue increases to more than EUR 50 million in 2017L.B. Bohle focuses on QbCon®, increased efficiency and comprehensive service in 2018
The new management duo of Tim Remmert and Thorsten Wesselmann concluded their first year with record sales of more than EUR 50 million. “Following this he solid growth, we will mainly focus on three aspects in 2018,” states Managing Director Tim Remmert. “With our QbCon® pilot plant, we want to establish continuous processes as a standard in the pharmaceutical industry. Secondly, in light of increasing costs, we are working on higher efficiency. And our third goal is to set up a comprehensive range of services.” In the year of ACHEMA, the key objective is a sustainable increase in turnover.
“We had a good year, but our earnings did not keep up with the sales increase,” reports Managing Director Tim Remmert. Increased costs as well as high up-front payments for research and development had a strong impact. At the same time, the market development of the continuous processes turned out to be a lengthy process. However, this topic gained new momentum with the international